Lonza Group

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company specializes in technologies that enhance the efficacy and tolerability of ADCs. Its flagship offering, GlycoConnect, utilizes enzymatic modification of naturally occurring glycan anchor points on antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer agents. Additionally, Synaffix provides HydraSpace, a linker technology designed to improve payload solubility and reduce aggregation potential. The company's portfolio also includes a metal-free click chemistry approach applicable across pharmaceutical and academic sectors. With a strong patent portfolio, Synaffix ensures protection for its innovations through at least 2035, positioning itself as a key player in the development of proprietary ADCs from a wide range of antibodies.

Indapta Therapeutics is a privately held biotechnology company that focuses on the development of a natural killer (NK) cell therapy platform aimed at treating various blood and solid tumor cancers. The company specializes in commercializing a proprietary, off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the cytotoxicity of antibody therapies. By harnessing the potent antibody-dependent cellular cytotoxicity (ADCC) activity of these NK cells, Indapta Therapeutics enables healthcare providers to offer innovative treatment options for patients battling cancer.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Octane Biotech is a medical technology company with advanced bioreactors, bioprocesses, and biomaterials for regenerative medicine solutions and bioengineering.

Micromacinazione S.A. is an engineering company based in Molinazzo di Monteggio, Switzerland, specializing in jet-mill technologies and micronization services for the pharmaceutical and fine chemical industries. Founded in 1970, the company offers tailored micronization solutions that enhance the performance of active pharmaceutical ingredients (APIs) and highly potent compounds, ensuring safety for personnel and the environment. Its services include research and development in pharmaceutical powder technologies, process development, and the design and manufacturing of equipment such as jet mills, glove boxes, and pneumatic conveyors. Micromacinazione's innovative approaches also focus on improving the solubility of poorly soluble drugs, catering to the evolving needs of the pharmaceutical sector. As of 2017, it operates as a subsidiary of Lonza Group Ltd.

PharmaCell is a leading provider of cell-culturing services, specializing in the manufacture of cellular therapies and regenerative medicine. Operating from GMP-certified facilities in Maastricht and Geleen, the company collaborates with top-tier organizations in the commercial cell therapy sector. PharmaCell leverages its extensive network to support research and development companies, facilitating the transition of innovative products from the laboratory to clinical application. By focusing on the production and support of commercial cell therapy products, PharmaCell aims to unlock the potential of cell therapies, ultimately enhancing patient healthcare outcomes.

HansaBioMed OU, founded in 2007 and located in Tallinn, Estonia, focuses on research and development in the field of exosome sciences and related technologies. The company specializes in the testing and validation of cancers and neurodegenerative diseases, offering products that include proprietary platforms, kits, reagents, and equipment for exosome research. HansaBioMed is particularly known for its expertise in the purification, enrichment, and characterization of extracellular vesicles (EVs), as well as providing scalable and automated purification solutions from various biological sources. Additionally, the company offers services such as bulk and single EV characterization and biomarker assessment through advanced techniques like mass spectrometry and RNA sequencing. As of May 2017, HansaBioMed operates as a subsidiary of Lonza Group Ltd.

Exosomics focuses on creating innovative tests for cancer screening and liquid biopsy through the analysis of circulating extracellular vesicles. The company specializes in biotechnology equipment that enhances the pre-analytical processes necessary to isolate tumor-derived extracellular vesicles and exosomes from human biofluids. By extracting genomic DNA and RNA from these components, Exosomics aims to provide reliable and cost-effective diagnostic solutions. This approach facilitates improved treatment options for cancer patients by enabling more accurate detection and monitoring of the disease.

Capsugel is a prominent developer and manufacturer of high-quality dosage forms and solutions, headquartered in Morristown, New Jersey. The company specializes in producing a variety of capsules, including inhalation, gelatin, clinical, and polymer capsules. These products are designed to enhance the bioavailability, targeted delivery, and overall efficacy of biopharmaceutical, consumer health, and nutritional products. With a strong focus on innovation and reliability, Capsugel serves healthcare companies globally, providing the scientific and engineering expertise necessary to advance the development of better medicines and nutritionals. The company has established a reputation as a leading provider of empty, two-piece hard capsules and is noted for its commitment to quality and value creation in the healthcare sector.

ConnectedYard Inc., based in Campbell, California, specializes in smart technology for outdoor living, starting with pool and hot tub care through its product, pHin. This innovative solution combines a Bluetooth and Wi-Fi-enabled water monitor with a mobile app that simplifies water management. The app alerts users when water chemistry requires adjustment, providing clear dosing instructions for necessary chemicals. Additionally, it offers convenient access to a network of qualified pool service technicians, facilitating on-demand assistance. As ConnectedYard continues to develop its offerings, it aims to expand its smart solutions to cover various aspects of outdoor living, including irrigation and lighting, enhancing the overall experience of backyard management.

InterHealth Nutraceuticals is a company that specializes in the research, development, marketing, and distribution of proprietary branded nutraceutical ingredients. Its products are sold globally to manufacturers of dietary supplements, functional foods, beverages, and cosmetic products. The company is recognized for its high-quality ingredients, extensive research programs, and strong customer service. InterHealth's notable ingredient brands include Super CitriMax, UC-II, ChromeMate, and L-OptiZinc. Since the introduction of its first product, ChromeMate, in 1987, InterHealth has established a reputation for innovation and quality in the nutraceutical industry. The company is committed to exploring new value-added ingredients and collaborates with clients to create proprietary blends tailored to their health supplement needs.

TRL is a fast-growing hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications. Triangle Research Labs has facilities based in Research Triangle Park, North Carolina (USA). Triangle Research Labs was established in 2012 and has quickly gained a reputation for high-quality products and a unique ability to understand each customer’s specific needs. This combination makes TRL a great asset to Lonza’s mission of serving customers in the bioresearch space through a culture of trust and care.

Diacon Technologies Ltd. is a supplier of anti-sapstain chemicals and delivery systems.

Zelam Limited is a New Plymouth, New Zealand-based company that specializes in the research, development, production, and marketing of crop protection products for both domestic and international markets. Established in 1988, the company offers a diverse range of products, including fungicides, herbicides, insecticides, and foliar nutrients, catering to the needs of the agricultural sector. In addition to crop protection, Zelam manufactures and treats engineered wood products and conducts testing in its micro laboratory, with trial operations extending to New Zealand, Australia, and Hawaii. The company markets its products under several brand names, including TAG G2, Vixen, Taratek, and Permatek. Zelam Limited was previously known as Taranaki Nuchem Ltd. and rebranded in April 2006. As of August 2015, it operates as a subsidiary of Lonza Group Ltd.

Odyssey Thera, Inc. is a biopharmaceutical company based in San Ramon, California, dedicated to identifying and developing innovative therapies for cancer treatment. The company employs a cellular pharmacology strategy to decipher biologically-relevant pathways in living human cells, enhancing the processes of target and drug discovery. Odyssey Thera's product pipeline features small molecule inhibitors that target crucial signaling nodes in human cancer cells. Originally incorporated as Odyssey Pharmaceuticals in 2002, the company has evolved to focus on advancing methods for environmental chemical toxicity assessment alongside its therapeutic development efforts.

Arch Chemicals, Inc., is a global specialty chemical company based in Norwalk, Connecticut, involved in two main business segments: treatment products and performance products. Treatment products include chemicals to sanitize drinking water and swimming pools; industrial biocides, used to inhibit the growth of microorganisms in metal working fluids, paint, and other coatings; industrial wood preservatives and fire retardants; stains and lacquers to coat wood; and active ingredients and preservatives used in shampoos, cosmetics, and other personal care products. Arch's performance products include polyols used to make adhesives, sealants, and coatings; glycols for making antifreeze, cleaning products, and consumer goods; and hydrazine hydrate, used to make drugs, treat water, and blowing agents that strengthen plastics and rubbers by expanding them. In 2004 Arch sold off most of its microelectronic materials business segment, which provided slurry used by semiconductor manufacturers to remove and polish surfaces. In addition to 16 U.S. locations, Arch maintains operations in 20 other countries around the world. A spinoff of the Olin Corporation in 1999, Arch is a public company listed on the New York Stock Exchange.

Vivante GMP Solutions is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics.

Moda Technology Partners is a commercial software company dedicated to enhancing automation and regulatory compliance within pharmaceutical manufacturing. The company develops a mobile data acquisition platform that empowers organizations to streamline their quality control processes for pharmaceuticals and consumer products. By leveraging mobile computing technology, Moda's software solutions aim to increase operational efficiency, improve product quality, and reduce manufacturing costs for their clients in the pharmaceutical sector.

AlgoNomics is a Belgium-based biotechnology company specializing in structural bioinformatics services aimed at advancing the development of therapeutics in the field of immunotherapy. The company boasts a proprietary technology platform that includes advanced tools for analyzing protein-protein and protein-peptide interactions. Among its key offerings is the Epibase platform, which focuses on T-cell epitope identification across diverse population groups. This platform plays a crucial role in the discovery of vaccines and therapeutic proteins, facilitating immunogenicity screening to support the development of biotherapeutics. Through its innovative approach, AlgoNomics is positioned to make significant contributions to the biopharmaceutical industry.

Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

Amaxa Biosystems GmbH specializes in developing and commercializing gene transfer technologies, notably through its Nucleofector Technology, which facilitates the non-viral transfer of various substrates, including DNA, RNA, and peptides into cells. The company provides a range of products and services, including transfection reagents, antibiotics for combating microbial contamination, and expression vectors for producing fluorescent proteins in mammalian cells. Amaxa's solutions are utilized in primary cell research and are available in multiple countries, including Canada, China, and Japan. Founded in 1998 and headquartered in Cologne, Germany, Amaxa has been a subsidiary of Lonza Group AG since 2008.

SAM Electron Technologies develops an electrochemical cerium-based oxidation technology.

UCB-Bioproducts provides chemical peptide manufacturing services.